About Us

About us

We are Valerio Therapeutics, a clinical-stage biotechnology company pioneering the development of DNA decoy therapies. Using our revolutionary platON™ DNA decoy platform, we are developing innovative treatments that target and disrupt intracellular processes in tumors and inflammatory diseases by acting as decoys to hijack pathways critical to maintaining pathology.

Our Team

Management

Shefali Agarwal, MD

President &
Chief Executive Officer

Wael Jdey, PhD

Head
of Preclinical

Huiping Jiang

Chief
Regulatory Officer

Joseph Donahue

Executive Director
of Clinical Operations

Donna Cabral-Lilly, PhD

Vice President
Head of CMC

Pam Slatcher, MHS, MT, PA

Head
of Global PV

Robin Sutherland

Vice President – Global
Head of Human Resources

Joyce Carey

Executive Director
Finance – Head of FP&A

Laura Sierra

Head of
Clinical Research

Anand Rajarethinam

VP, Clinical Data Sciences
and Alliance Strategy

Michael Snitkovsky

Head of
Program Management

Daniel Powers

Medical Advisor
in Residence

Board of Directors

Shefali Agarwal, MD

President &
Chief Executive Officer

Khalil Barrage

Director
Representing Invus

Robert L. Coleman

Independent
Director

Bryan Giraudo

Independent
Director

Julien Miara

Director
Representing Invus

Jack Mallet

Independent
Director

Nicolas Trebouta

Director Representing Financière
De La Montagne

Scientific Advisory Committee

Caroline Robert, M.D., Ph.D

Scientific
Advisor

Gilbert Chu, MD, PhD

Scientific
Advisor

Gilles Favre, PhD

Scientific
Advisor

Lorenzo Galluzzi, PhD

Scientific
Advisor

Ruth Plummer, MD, PhD

Scientific
Advisor

Company Profile

Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel and first-in-class DNA-decoy therapies targeting proteins implicated in tumors and inflammatory disease processes.

Our therapeutic strategy focuses on fighting intracellular pathways dysregulations, in fields that pose greater therapeutic challenges. Our approach is based upon unique mechanisms of action on intracellular DNA-binding proteins. We focus on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in human cancer and inflammatory indications with high unmet needs.

We seek to transform breakthrough scientific opportunities into treatments through translational and clinical expertise, developing products to the stage where they are compelling opportunities for partners. Therefore, we are focused on advancing products from the preclinical stage to optimal inflection points (usually phase 2 clinical proof-of-concept studies). Once proof of concept is established, we seek to monetize the assets through various types of deals, thereby generating revenue and value.

Our inherent value rests on the significant potential of our product pipeline and the expertise of our highly professional team.

Our People

We are a passionate team of scientists and business professionals, with robust in-house translational and clinical expertise to drive our programs to their maximum value-inflection points and generate value and growth through collaborations.

We are led by a senior management team with extensive life sciences industry experience in international venues and a proven track record in translational research, clinical development, regulatory affairs and business development.

Our Science

Our proprietary platform of decoy oligonucleotides, platON™, generates innovative compounds targeting intracellular DNA-binding proteins implicated in tumors and inflammatory disease processes through a decoy mechanism.

This mechanism of action is unlike any other investigated or available today in these fields and has the capacity to address new and multiple intracellular pathways.